Table 2.

Model inputs for the base-case scenario. Also shown are ranges used for the probabilistic sensitivity analysis

Parameter	Base case value	Sensitivity analysis range	References
Discontinuation and switch
Treatment discontinuation
Without AEs	6.4 % per month	3.0–14.5 %	Base case and upper limit: Wagg et al. [21]; Sánchez-Ballester et al. [22]; lower limit: assumption
With AEs	90 % per month	50–100 %	Expert opinion
Treatment switcha	26.1 %	15.3–50.0 %	Base case: Odeyemi et al. [23]; sensitivity analysis: D’Souza et al. [38]/assumption
Treatment restartb	5.6 % per month	0–20.0 %	Expert opinion
BTX injection	0.01 % per month	0–0.05 %	Expert opinion
Success with BTX	79 %	50–100 %	Wu et al. [24]
Adverse events
Dry mouth
Mirabegron 50 mg	2.8 %	2.1–3.5 %	SCORPIO [15]
Tolterodine ER 4 mg	10.1 %	8.7–11.5 %	SCORPIO [15]
Constipation
Mirabegron 50 mg	1.6 %		SCORPIO [15]
Tolterodine ER 4 mg	2.0 %		SCORPIO [15]

AE adverse event, BTX botulinum toxin, ER extended release, OAB overactive bladder syndrome

^a Among patients discontinuing OAB treatment

^b Split between different medications was assumed to be one-third each for initial, second- and third-line treatments